Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Blend Therapeutics, a biotechnology company, is set to develop innovative combination medicines with novel pharmacological profiles designed to target distinct disease pathways with optimal efficacy and safety.
Subscribe to our email newsletter
The company is founded based on its proprietary Maestro platform for integrative combination medicines.
It was founded by leaders in the fields of chemistry and nanomedicine from the Massachusetts Institute of Technology (MIT) and Harvard Medical School.
Blend also announced the establishment of its Scientific Advisory Board (SAB) whose initial members will include eight thought leaders in the fields of chemistry, cancer biology, immunology and medicine from various academic institutions and medical centers.
Blend’s SAB is believed to foster the progress its proprietary Maestro platform to create integrated, pharmacologically controlled combination medicines that more predictably, effectively, and safely target the multiple mechanisms underlying complex diseases.